{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:46:18Z","timestamp":1794008778046,"version":"4.8.0"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"unspecified","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministry of Science, Innovation and Universities","doi-asserted-by":"crossref","award":["PCI2024-153490"],"award-info":[{"award-number":["PCI2024-153490"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"crossref","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/CRTF24\/24601"],"award-info":[{"award-number":["FS\/CRTF24\/24601"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"crossref","award":["NIHR301338"],"award-info":[{"award-number":["NIHR301338"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"British Heart Foundation Accelerator Award","award":["AA\/18\/4\/34221"],"award-info":[{"award-number":["AA\/18\/4\/34221"]}]},{"name":"Spanish Instituto de Salud Carlos III","award":["CIBERCV CB16\/11\/00483"],"award-info":[{"award-number":["CIBERCV CB16\/11\/00483"]}]},{"name":"Spanish Instituto de Salud Carlos III","award":["PI21\/00946"],"award-info":[{"award-number":["PI21\/00946"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2026,1,15]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Plasma concentrations of procollagen type-I C-terminal pro-peptide (PICP) and collagen type-I C-terminal telopeptide (CITP) may reflect collagen turnover and systemic fibrosis. We investigated the effect of pirfenidone, an anti-fibrotic agent, on PICP and CITP, and their association with myocardial fibrosis, using cardiovascular magnetic resonance to measure extracellular volume (ECV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the trial (Pirfenidone in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction), PICP, CITP and PICP:CITP ratio were measured at baseline and follow-up in patients with ECV\u226527% randomised (n=94) to pirfenidone or placebo, and at baseline only in patients who were not randomised because of ECV&lt;27% (n=13).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no association between baseline myocardial ECV and baseline log PICP, log CITP and log PICP:CITP ratio (p=0.19, p=0.13, p=0.60, respectively). Treatment with pirfenidone did not alter PICP, but reduced CITP and increased PICP:CITP ratio at 13 and 26 weeks (all p&lt;0.05) but not at 52 weeks. After multivariable adjustment, there was a weak relationship between change in myocardial ECV and change in log PICP (R\n                      <jats:sup>2<\/jats:sup>\n                      0.16, p=0.01) and log CITP (R\n                      <jats:sup>2<\/jats:sup>\n                      0.12, p=0.04), but not log PICP:CITP ratio (p=0.56).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with stable heart failure with preserved ejection fraction, pirfenidone treatment had no sustained effect on plasma levels of PICP and CITP at 52 weeks. Changes in ECV during treatment with pirfenidone are associated with changes in plasma PICP and CITP, suggesting a weak association between changes in collagen volume\/mass and plasma markers of collagen turnover.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2025-003596","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:50:15Z","timestamp":1770735015000},"page":"e003596","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of pirfenidone on plasma markers of collagen turnover in patients with heart failure, preserved left ventricular ejection fraction and myocardial fibrosis"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02932566","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0089-6180","authenticated-orcid":false,"given":"Nicholas","family":"Black","sequence":"first","affiliation":[{"name":"BHF Manchester Centre for Heart and Lung Magnetic Resonance Research, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, Manchester, M13 9LT, UK, Manchester, UK"},{"name":"Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Lewis","sequence":"additional","affiliation":[{"name":"Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2030-9761","authenticated-orcid":false,"given":"Fardad","family":"Soltani","sequence":"additional","affiliation":[{"name":"BHF Manchester Centre for Heart and Lung Magnetic Resonance Research, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, Manchester, M13 9LT, UK, Manchester, UK"},{"name":"Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Dodd","sequence":"additional","affiliation":[{"name":"Department of Health Data Science, Institute of Population Health, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik B","family":"Schelbert","sequence":"additional","affiliation":[{"name":"Allina Health Minneapolis Heart Institute, Allina Health, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Ravassa","sequence":"additional","affiliation":[{"name":"Program of Cardiovascular Research, Centro de Investigaci\u00f3n M\u00e9dica Aplicada, Universidad de Navarra, and IdiSNA and CIBERCV, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Program of Cardiovascular Research, Centro de Investigaci\u00f3n M\u00e9dica Aplicada, Universidad de Navarra, and IdiSNA and CIBERCV, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5986-6528","authenticated-orcid":false,"given":"Arantxa","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Program of Cardiovascular Research, Centro de Investigaci\u00f3n M\u00e9dica Aplicada, Universidad de Navarra, and IdiSNA and CIBERCV, Pamplona, Spain"},{"name":"Department of Cardiology and Cardiac Surgery, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-7016","authenticated-orcid":false,"given":"John G","family":"Cleland","sequence":"additional","affiliation":[{"name":"British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A","family":"Miller","sequence":"additional","affiliation":[{"name":"BHF Manchester Centre for Heart and Lung Magnetic Resonance Research, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, Manchester, M13 9LT, UK, Manchester, UK"},{"name":"Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"2026021006500534000_13.1.e003596.1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa324"},{"key":"2026021006500534000_13.1.e003596.2","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-15-92"},{"key":"2026021006500534000_13.1.e003596.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.043250"},{"key":"2026021006500534000_13.1.e003596.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.032"},{"key":"2026021006500534000_13.1.e003596.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.11.031"},{"key":"2026021006500534000_13.1.e003596.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12968-018-0477-4","article-title":"Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction","volume":"20","author":"Roy","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026021006500534000_13.1.e003596.7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jamacardio.2017.2511","article-title":"Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome","volume":"2","author":"Schelbert","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026021006500534000_13.1.e003596.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.089409"},{"key":"2026021006500534000_13.1.e003596.9","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009535","article-title":"Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis","volume":"12","author":"Yang","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026021006500534000_13.1.e003596.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2019.03.034"},{"key":"2026021006500534000_13.1.e003596.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2019.04.025"},{"key":"2026021006500534000_13.1.e003596.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-00504-1"},{"key":"2026021006500534000_13.1.e003596.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028134","article-title":"In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion","volume":"6","author":"Shi","year":"2011","journal-title":"PLoS ONE"},{"key":"2026021006500534000_13.1.e003596.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01452-0"},{"key":"2026021006500534000_13.1.e003596.15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10557-019-06876-y","article-title":"Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial","volume":"33","author":"Lewis","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026021006500534000_13.1.e003596.16","doi-asserted-by":"publisher","DOI":"10.3758\/BRM.41.4.1149"},{"key":"2026021006500534000_13.1.e003596.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.04.026"},{"key":"2026021006500534000_13.1.e003596.18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.912774"},{"key":"2026021006500534000_13.1.e003596.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.311148"},{"key":"2026021006500534000_13.1.e003596.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80686-9"},{"key":"2026021006500534000_13.1.e003596.21","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.14.1729"},{"key":"2026021006500534000_13.1.e003596.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.12.052"},{"key":"2026021006500534000_13.1.e003596.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.571653"},{"key":"2026021006500534000_13.1.e003596.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.072"},{"key":"2026021006500534000_13.1.e003596.25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u201cOMics\u201d in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021006500534000_13.1.e003596.26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2023.01.088","article-title":"Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials","volume":"377","author":"Ferreira","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026021006500534000_13.1.e003596.27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ejhf.3101","article-title":"Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials","volume":"26","author":"Ferreira","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021006500534000_13.1.e003596.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00005209"},{"key":"2026021006500534000_13.1.e003596.29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10741-021-10175-w","article-title":"Pirfenidone as a novel cardiac protective treatment","volume":"27","author":"Aimo","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2026021006500534000_13.1.e003596.30","doi-asserted-by":"crossref","unstructured":"Li C , Han R , Kang L , et al . Pirfenidone controls the feedback loop of the AT1R\/p38 MAPK\/renin-angiotensin system axis by regulating liver X receptor-\u03b1 in myocardial infarction-induced cardiac fibrosis. Sci Rep 2017;7. doi:10.1038\/srep40523","DOI":"10.1038\/srep40523"},{"key":"2026021006500534000_13.1.e003596.31","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2011.139"},{"key":"2026021006500534000_13.1.e003596.32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.624320"},{"key":"2026021006500534000_13.1.e003596.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2010.04.030"},{"key":"2026021006500534000_13.1.e003596.34","doi-asserted-by":"crossref","unstructured":"Chirinos JA , Zhao L , Reese-Petersen AL , et al . Endotrophin, a Collagen VI Formation-Derived Peptide, in Heart Failure. NEJM Evid 2022;1. doi:10.1056\/evidoa2200091","DOI":"10.1056\/EVIDx2200258"},{"key":"2026021006500534000_13.1.e003596.35","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000147181.65298.4D"},{"key":"2026021006500534000_13.1.e003596.36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2025-003596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:50:20Z","timestamp":1770735020000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2025-003596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/openhrt-2025-003596"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2025-003596","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}